| ALKERMES PLC DL-,01 |
| Irland |
| Gesundheit |
| IE00B56GVS15 / A1JKVH |
| 8AK (Frankfurt) / ALKS (NASDAQ) |
| FRA:8AK, ETR:8AK, 8AK:GR, NASDAQ:ALKS |
| - |
| https://www.alkermes.com/ |
|
Alkermes plc is an Ireland-based, fully integrated global biopharmaceutical company focused on developing and commercializing innovative medicines in neuroscience. It specializes in treatments for serious mental illnesses, addiction, schizophrenia, b..
>Volltext.. |
| 7752.33 Mio. EUR |
| 8678.61 Mio. EUR |
| 1373.89 Mio. EUR |
| 203.19 Mio. EUR |
| 134.3 Mio. EUR |
| 0.82 EUR |
| 1390.91 Mio. EUR |
| 309.15 Mio. EUR |
| 225.3 Mio. EUR |
| 0.85 |
| -3.36% |
| -59.46% |
| - |
| - |
| - |
| ALKERMES |
| 28.07.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|